National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, NSW, Australia.
National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia.
Vaccine. 2023 May 22;41(22):3422-3428. doi: 10.1016/j.vaccine.2023.04.041. Epub 2023 Apr 18.
Determining background rates of medical conditions identified as adverse events of special interest (AESI) that may occur following COVID-19 vaccination is important for contextualising and investigating potential vaccine safety signals.
We conducted a retrospective population-based cohort study using linked emergency department, hospitalisation and death data for 2017 and 2018 from Australia's most populous state, New South Wales. Incident cases of select neurological conditions, arterial or venous thromboembolic conditions, secondary thrombocytopenia, myocarditis/pericarditis, and unique events of anaphylaxis and generalised convulsions were identified using internationally agreed upon diagnostic (ICD-10) codes. State-specific rates per 100,000 person-years were calculated, with further stratification by age group and sex where clinically relevant to the condition, and the number of expected cases nationally in one and 6 weeks was estimated.
Background rates of selected neurological conditions were low with the exception of generalised convulsions for which 1,599-1,872 cases were estimated nationally in a 1-week period in the absence of vaccination. Using a narrow case definition, rates of Guillain-Barré Syndrome (3.9 per 100,000 person-years) were higher than international rates reported elsewhere. Thromboembolic and cerebral venous sinus thrombosis event rates increased with age. Myocarditis occurred more commonly in males, and was highest in males aged 18-24 years, with an estimated 1-4 cases expected nationally in a 1-week period.
Using routinely collected linked healthcare data provides localised estimates of background rates of new onset or periodic AESI which enables rapid estimation of observed-versus-expected rates of events reported following COVID-19 vaccination. This Australian-specific analysis contributes AESI background rates which can be compared with those from other countries to enhance understanding of geographic variability in the frequency of specific AESI in the absence of vaccination, and can be utilised for signal detection during program implementation.
确定与 COVID-19 疫苗接种相关的特殊关注不良事件(AESI)的医疗条件的背景发生率对于理解和调查潜在的疫苗安全信号非常重要。
我们使用澳大利亚人口最多的州新南威尔士州 2017 年和 2018 年的急诊、住院和死亡数据进行了一项回顾性基于人群的队列研究。使用国际公认的诊断(ICD-10)代码确定了选定的神经状况、动脉或静脉血栓栓塞状况、继发性血小板减少症、心肌炎/心包炎以及过敏反应和全身性惊厥的独特事件的发病情况。计算了每 10 万人年的特定州发病率,并在与疾病相关的情况下按年龄组和性别进一步分层,估计了全国范围内 1 周和 6 周内预期的病例数。
除了在没有疫苗接种的情况下,全国预计在 1 周内有 1599-1872 例全身性惊厥外,选定神经状况的背景发生率较低。使用狭义的病例定义,格林-巴利综合征的发病率(每 10 万人年 3.9 例)高于其他地方报告的国际发病率。血栓栓塞和脑静脉窦血栓形成的发病率随年龄增长而增加。心肌炎更常见于男性,在 18-24 岁的男性中发病率最高,全国预计在 1 周内有 1-4 例。
使用常规收集的医疗数据提供了新发病例或周期性 AESI 的局部背景发生率估计值,这使得可以快速估计 COVID-19 疫苗接种后报告的事件的观察到的与预期的发生率。这种澳大利亚特有的分析提供了 AESI 的背景发生率,可以与其他国家的发生率进行比较,以增强在没有接种疫苗的情况下了解特定 AESI 频率的地理变异性,并可用于在计划实施期间进行信号检测。